JS207 / Shanghai Junshi Bioscience, DotBio - LARVOL DELTA

A Phase 2 Study of JS207, a PD-1/VEGF Bispecific Antibody, Plus Chemotherapy in Patients With Unresectable Stag III NSCLC (IASLC-WCLC 2026) - P2 | "Conclusions : The combination of JS207 and chemotherapy demonstrated an encouraging surgical conversion rate and pCR rate with an acceptable safety profile in patients with unresectable NSCLC. These findings provide valuable clinical data for further confirmatory studies."

Bispecific • Clinical • P2 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy (clinicaltrials.gov) - P2 | N=18 | Terminated | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=66 ➔ 18 | Recruiting ➔ Terminated; The research and development strategy was adjusted, so the research was suspended

Enrollment change • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma: updated results from a Phase Ⅱ study (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor

A phase 2 trial of JS207 (PD-1/VEGF bispecific antibody) plus chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC) (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer (clinicaltrials.gov) - P3 | N=560 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P3 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC (clinicaltrials.gov) - P2 | N=69 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2027 ➔ May 2028 | Trial primary completion date: Nov 2025 ➔ Dec 2027

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC (clinicaltrials.gov) - P2 | N=76 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2026 ➔ Apr 2027

Enrollment closed • Trial primary completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • RET • ROS1

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - P1 | N=98 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=59 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting | N=93 ➔ 59 | Trial primary completion date: May 2026 ➔ Dec 2026

Enrollment change • Enrollment closed • Monotherapy • Trial primary completion date • Oncology • Solid Tumor

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer (clinicaltrials.gov) - P2 | N=864 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy (clinicaltrials.gov) - P2 | N=78 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=42 ➔ 78 | Trial completion date: Apr 2027 ➔ Apr 2028 | Trial primary completion date: Sep 2025 ➔ Sep 2026

Enrollment change • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • ERBB3 • HER-2 • KRAS • NTRK • PD-L1 • RET • ROS1

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=480 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

JS212 Combination Therapies in Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Dec 2026 ➔ Dec 2027

Enrollment open • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor

JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study (AACR 2026) - P2 | "Conclusion The combination of JS207 and JS007 demonstrated promising efficacy with an acceptable safety profile as first line treatment of advanced HCC. The randomized expansion phase of this study is ongoing."

Bispecific • Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer (AACR 2026) - P2 | "JS207 in combination with XELOX as first-line treatment for mCRC patients demonstrated an acceptable safety profile and promising efficacy."

Bispecific • Clinical • Combination therapy • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor

#CT159: Preliminary results from a phase 2 study evaluating JS207 in combination with JS007 as first-line treatment for advanced hepatocellular carcinoma (HCC) (GlobeNewswire) - "Shanghai Junshi Biosciences...announced that early clinical results from four studies across its innovative pipeline were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting....As of March 20, 2026, a total of 26 patients had received JS207 plus JS007, including 7 patients in the safety run-in period and 19 patients in the randomized expansion phase. Among the 22 evaluable patients, the objective response rate (ORR) reached 45.5% while the disease control rate (DCR) was 86.4%. JS207 plus JS007 was well-tolerated, with no dose-limiting toxicities (DLT) observed during the safety run-in period."

P2 data • Hepatocellular Cancer

#CT152: Preliminary results from a phase 2 study evaluating JS207 in combination with chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC) (GlobeNewswire) - "Shanghai Junshi Biosciences...announced that early clinical results from four studies across its innovative pipeline were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting....As of January 13, 2026, 32 patients had been enrolled and received JS207 plus XELOX, including 9 in the safety run-in phase and 23 in the dose-expansion phase. Among the 31 efficacy-evaluable patients, 22 achieved a partial response (PR) and 8 achieved stable disease (SD), resulting in an ORR of 71.0% and a DCR of 96.8%. Due to the relatively short follow-up duration, median progression-free survival (PFS) and median duration of response (DoR) have not yet been reached, and the longest duration of response remained ongoing at 8 months."

P2 data • Colorectal Cancer

A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=480 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Monotherapy • New P2 trial • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

JS212 Combination Therapies in Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) (GlobeNewswire) - "Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in combination with Antengene’s ATG-037, an oral small-molecule CD73 inhibitor, in patients with solid tumors in Chinese Mainland, with the goal of identifying clinical signals across multiple tumor types."

Licensing / partnership • Solid Tumor

A Phase II Clinical Study of JS207 (anti-PD-1/VEGF bispecific antibody) Combined with Platinum-based Doublet Chemotherapy in Subjects with Stage II-III Non-small Cell Lung Cancer (ChiCTR) - P2 | N=76 | Recruiting | Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

New P2 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • RET • ROS1

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer (clinicaltrials.gov) - P2 | N=864 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P2 trial • Lung Cancer • Oncology • Solid Tumor

A phase I study of JS207, a PD-1/VEGF bispecific antibody, in patients with advanced malignancies (ESMO Asia 2025) - P1 | "JS207 is engineered on the backbone of toripalimab with a VEGFA-specific nanobody inserted between Fab and Fc domains. JS207 demonstrated acceptable safety and promising monotherapy efficacy in solid tumors. JS207 is being evaluated in multiple phase II studies as monotherapy or in combination with standard care."

Clinical • Metastases • P1 data • Colorectal Cancer • Hepatocellular Cancer • Kidney Cancer • Lung Cancer • Microsatellite Instability • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • MSI • PD-1 • PD-L1

Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for a phase II/III clinical study of JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, for the neoadjuvant treatment of non-small cell lung cancer (NSCLC) patients. (TipRanks)

IND • New P2/3 trial • Non Small Cell Lung Cancer

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor